ARCHIVES

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

Surgery Without Radiation Found Inadequate for DCIS

December 26, 2003

DCT Advisors Okay Two New RFA Concepts In Clinical Research, Biodiversity Groups

November 8, 1991

Regular NSAIDs Use Protects Smokers From Lung Cancer

March 28, 2003

Intensive Chemo Equivalent To Transplant For MCL

December 26, 2008

In Brief: NCHSR Says Autologous Marrow Transplant Is A “Reasonable Therapeutic Alternative”

August 11, 1989

NCI Adds $700,000 to CCOP Budget, Makes Four New Awards

June 9, 1989